62021-36-7

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 3-cyclopropylpropanoate is used as an intermediate in the synthesis of 2-cyclopropylethyl carbonyl compounds for the development of pharmaceuticals. Its cyclopropane ring and ester group provide a structural foundation that can be further modified to create bioactive molecules with potential therapeutic applications.
Used in Chemical Synthesis:
In the field of organic chemistry, ethyl 3-cyclopropylpropanoate serves as a versatile building block for the preparation of a variety of organic compounds. Its reactivity and unique structural features make it a valuable component in the synthesis of complex organic molecules, including those with potential applications in materials science, agrochemicals, and other specialty chemical industries.
Used in Research and Development:
Ethyl 3-cyclopropylpropanoate is also utilized in academic and industrial research settings to explore its chemical properties and potential applications. Its unique structure allows researchers to investigate new synthetic pathways and develop innovative methods for the preparation of cyclopropane-containing compounds, which could lead to the discovery of new drugs, materials, or other valuable products.

Upstream product

• 5808-99-1 ethyl 3-(3-cyclopropyl)propenoate 
• 21014-26-6 ethyl 3-cyclopropaneprop-2-enoate 
• 64-17-5 ethanol 
• 49642-18-4 2,4,4,6-tetrachloro-hexanoic acid methyl ester 

Downstream Products

• 123-66-0 Ethyl hexanoate 
• 25415-67-2 ethyl isocaproate 
• 5618-03-1 3-cyclopropanepropionic acid 

Relevant academic research and scientific papers

HUMAN PLASMA KALLIKREIN INHIBITORS

Disclosed are compounds of formula I, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.

Preparation method of cyclopropylpropionic acid

The invention relates to a synthetic method of cyclopropylpropionic acid. Technical problems of synthesis operation difficulty and expensive raw material are solved. A conventional industrial raw material cyclopropanecarboxaldehyde is used as a starting raw material and triethyl phosphonoacetate undergo a Wittig reaction to obtain 3-cyclopropyl-ethyl acrylate; 3-cyclopropyl-ethyl acrylate and sodium borohydride undergo reduction of double bonds in the presence of Lewis acid to obtain 3-cyclopropyl-ethyl propionate; and 3-cyclopropyl-ethyl propionate is hydrolyzed under an alkaline condition so as to obtain cyclopropylpropionic acid. A chemical equation is as shown in the specification.

HUMAN PLASMA KALLIKREIN INHIBITORS

Disclosed are compounds of formula (I), as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.